GlobeNewswire by notified

AGC Biologics Names Regina Choi-Rivera New General Manager of Boulder, Colorado Mammalian Production Facility

Share

Boulder, Colo., Jan. 18, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced Regina Choi-Rivera as the new General Manager of the company’s large-scale biopharmaceutical mammalian production facility in Boulder. In this role, she assumes executive oversight and leadership and will manage strategic development and facility operations.

“We’re incredibly excited that Ms. Choi-Rivera is joining AGC Biologics as the General Manager at our Boulder facility. She brings tremendous experience in both GMP manufacturing and project management,” said AGC Biologics Executive Vice President of U.S. Operations, J.D. Mowery. “Her breadth of knowledge and proven leadership give me great confidence that she is the right leader for our team, as well as our customers.”

Ms. Choi-Rivera brings more than 25 years of experience in the biotech industry to this role and joins AGC Biologics after working for Samsung Biologics for more than eight years. While at Samsung Biologics she most recently served as Vice President, Head of Drug Product Business Unit. Prior to that Ms. Choi-Rivera was Vice President, Head of the Drug Substance Contract Manufacturing Business unit. Before her time at Samsung, she spent nearly a decade with Janssen Pharmaceutical’s research and development division, supporting pilot plant operations and managing outsourcing activities. Her background, expertise and education make her an ideal leader for this important facility in AGC Biologics’ expansive global network

"I am delighted to join AGC Biologics at such an exciting time of growth for the company and at such a transformational time for our industry," said Choi-Rivera. "The strong track record of biopharmaceutical innovation and technical capabilities at this facility, coupled with world-class talent, puts the Boulder site in position to help deliver important treatments that can truly change the lives of patients for years to come."

AGC Biologics acquired the Boulder Facility in June 2020, giving the company additional capacity and a significantly larger production scale for mammalian-based projects in the U.S. The Boulder site houses two 20,000-liter stainless steel cell bioreactors and has more than twenty acres of undeveloped land, creating opportunities for future expansion, including space for up to four more 20,000-liter bioreactors. The facility’s automation and cost-effective capabilities make it well-suited for high volume commercial production and high titer antibody processes.

About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,000 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Prime Office årsregnskab 202319.3.2024 10:00:00 CET | pressemeddelelse

Selskabsmeddelelse 199/2024 19. marts 2024 PRIME OFFICE A/S: TILFREDSSTILLENDE RESULTAT I EN OMSKIFTELIG VERDEN Økonomisk rapportering pr. 31.12.2023 Resultat af primær drift på 120,7 mio. DKK mod 114,0 i 2022.Resultat før skat på 114,3 mio. DKK mod 166,2 mio. i 2022. VÆKST I BOLIGSEGMENTET – K/S Danske Immobilien Huslejer stiger med 8,5% efter alle koncernens boligejendomme samles i K/S Danske Immobilien, og 4% i stigning uden intern handel. Omsætning/huslejer andrager 111,3 mio. DKK i 2023 mod 102,6 mio. DKK i 2022Udlejningsprocent på 98,5%Investeringer og vedligeholdelse over budget VÆKST I KONTORSEGMENTET - PO KONTORSELSKABER Huslejer stiger med 6,4% Omsætning/huslejer andrager 48,0 mio. DKK i 2023 mod 45,1 mio. DKK i 2022Udlejningsprocent på 99,5% FALD I ERHVERVSSEGMENTET – MC PROPERTY FUND HAMBURG Huslejer falder med 7% efter internt frasalg af boliger til K/S Danske Immobilien Omsætning efter frasalg af ejendomme 38,0 i 2023 40,9 mio. DKK i 2022.Udlejningsprocent på 97,6%. STIGE

Leading in health technology innovation: Philips one of the top patent applicants at European Patent Office19.3.2024 10:00:00 CET | Press release

March 19, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it is one of the leading patent applicants at the European Patent Office (EPO). Building on more than 130 years of innovation, Philips’ extensive global R&D programs and collaborations position the company at the forefront of health technology innovation. In 2023, Philips improved the health and well-being of 1.9 billion people with its innovations. With 607 MedTech patent applications in 2023, Philips is the second largest applicant in EPO's Patent Index 2023 in the field of medical technology. In total, Philips contributed 1,299 patent applications across various domains, solidifying its standing among the top 10 patent filers overall. Roy Jakobs, CEO of Royal Philips, said "At Philips, our purpose is to improve people’s health and well-being through meaningful innovation. As such, we see huge opportunities to make a difference through innovatio

Annual report 202319.3.2024 09:56:49 CET | Press release

To Nasdaq OMX Copenhagen A/S Public announcement no. 553 March 19th, 2024 ANNUAL REPORT FOR GLUNZ & JENSEN HOLDING A/S FOR THE FISCAL YEAR 2023 The annual report for the fiscal year 2023 was reviewed and approved at the Board of Directors meeting today. The Board of Directors announces the following consolidated financial statements for 2023 set for approval at the Annual General Meeting on April 10th, 2024. Please observe that the 2023 figures cover a 12-month period, whereas the 2022 figures cover a 9-month period. The annual report 2023 has the following key figures: The Group realized a revenue of DKK 143,3 million (2022: DKK 103,4 million). Gross profit totalled DKK 31,9 million (2022: DKK 27,5 million), equal to a gross profit margin of 22,2% (2022: 26,6%). EBITDA was DKK 10,8 million (2022: DKK 18,2 million). Profit before tax for the year totalled DKK 3,5 million (2022: DKK 15,3 million). The result is in line with the guidance to the market. The financial statements for 2023 a

HiddenA line styled icon from Orion Icon Library.Eye